Standard Biotools (LAB) Liabilities and Shareholders Equity (2010 - 2026)

Standard Biotools (LAB) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $639.1 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 10.27% year-over-year to $639.1 million in Q1 2026; TTM through Mar 2026 was $2.3 billion, a 10.79% decrease from a year earlier, with the FY2025 full-year figure at $567.8 million, down 7.28% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $639.1 million, up from $567.8 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for LAB reached as high as $777.7 million in Q1 2024 and fell as low as $271.9 million in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $504.2 million across 5 years, with a median of $539.6 million in 2025.
• Across the five-year window, Liabilities and Shareholders Equity jumped 109.24% in 2024 and dropped 25.47% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $390.3 million in 2022, then fell by 17.23% to $323.1 million in 2023, then jumped by 89.54% to $612.3 million in 2024, then decreased by 7.28% to $567.8 million in 2025, then gained by 12.57% to $639.1 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $639.1 million in Q1 2026, $567.8 million in Q4 2025, and $539.6 million in Q3 2025.